EUVIMEDEUVIMED entdecken
Crossref

Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange

Lucas Kühne iD, Paul Knöbl iD, Kathrin Eller iD, Johannes Thaler iD, Wolfgang R Sperr, Karoline Gleixner, Thomas Osterholt iD, Jessica Kaufeld iD, Jan Menne, Veronika Buxhofer-Ausch iD, Anja Mühlfeld, Evelyn Seelow und 13 weitere

Blood · 03.10.2024 · 144 (14) · 1486-1495

DOI: 10.1182/blood.2023023780 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 03.10.2024. Verfasst von Lucas Kühne und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department II of Internal Medicine and Center for Molecular Medicine Cologne, Faculty of Medicine and University Hospital Cologne, University of Colo…. Hauptthemen laut MEDLINE: Plasma Exchange, Single-Domain Antibodies, Purpura, Thrombotic Thrombocytopenic. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening autoimmune disorder caused by a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS13) deficiency. Caplacizumab, an anti–von Willebrand factor nanobody, is approved for iTTP treatment, reducing the need for therapeutic plasma exchange (TPE) and improving platelet count recovery and survival. We conducted a retrospective study on 42 acute iTTP cases in Austria and Germany, treated with a modified regimen aimed at avoiding TPE if platelet count increased after the first caplacizumab dose. Baseline characteristics and patient outcomes were compared with a control group of 59 patients with iTTP receiving frontline treatment with TPE, caplacizumab, and immunosuppression. The main outcome was the time to platelet count normalization. Secondary outcomes included clinical response, exacerbation, refractory iTTP, iTTP-related deaths, and the time to platelet count doubling. The median time to platelet count normalization was similar between the 2 cohorts (3 and 4 days; P = .31). There were no significant differences in clinical response, exacerbations, refractoriness, iTTP-related deaths, or time to platelet count doubling, reflecting the short-term treatment response. Four patients did not respond to the first caplacizumab dose, and TPE was subsequently initiated. Cytomegalovirus infection, HIV/hepatitis B virus coinfection, an ovarian teratoma with associated antiplatelet antibodies, and multiple platelet transfusions before the correct diagnosis may have impeded the immediate treatment response in these patients. In conclusion, caplacizumab and immunosuppression alone, without TPE, rapidly controlled thrombotic microangiopathy and achieved a sustained clinical response in iTTP. Our study provides a basis for TPE-free iTTP management in experienced centers via shared decision-making between patients and treating physicians.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plasma ExchangeSingle-Domain AntibodiesPurpura, Thrombotic ThrombocytopenicHumansFemaleMaleRetrospective StudiesAdultMiddle AgedPlatelet CountAgedYoung AdultAdolescentADAMTS13 ProteinPurpura, Thrombocytopenic, Idiopathic

Substanzen

caplacizumabSingle-Domain AntibodiesADAMTS13 Protein

Autor:innen und Institutionen

  • Department II of Internal Medicine and Center for Molecular Medicine Cologne, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Division of Hematology and Hemostasis, Department of Medicine 1, Medical University of Vienna, Vienna, Austria.
  • Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Department of Nephrology and Hypertension, Medical School Hannover, Hannover, Germany.
  • KRH Klinikum Mitte-Location Siloah, Hannover, Germany.
  • Department of Internal Medicine I with Hematology, Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinnen, Linz, Austria.

ORCID-Profile: Lucas Kühne, Paul Knöbl, Kathrin Eller, Johannes Thaler, Thomas Osterholt, Jessica Kaufeld, Veronika Buxhofer-Ausch, Polina Todorova, Sadrija Cukoski, Kristina Schönfelder, Timm Westhoff, Dennis A Eichenauer, Linus A Völker, Paul T Brinkkoetter

Zitieren

APA

Kühne, L., Knöbl, P., Eller, K., Thaler, J., Sperr, W. R., Gleixner, K., Osterholt, T., Kaufeld, J., Menne, J., Buxhofer-Ausch, V., Mühlfeld, A., Seelow, E., Schreiber, A., Todorova, P., Cukoski, S., Jabs, W. J., Özcan, F., Gäckler, A., Schönfelder, K., …, & Brinkkoetter, P. T. (2024). Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange. Blood, 144(14), 1486-1495. https://doi.org/10.1182/blood.2023023780

Vancouver

Kühne L, Knöbl P, Eller K, Thaler J, Sperr WR, Gleixner K, et al. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange. Blood. 2024;144(14):1486-1495. doi:10.1182/blood.2023023780

BibTeX
@article{Khne2024,
  author = {Kühne, Lucas and Knöbl, Paul and Eller, Kathrin and Thaler, Johannes and Sperr, Wolfgang R and Gleixner, Karoline and Osterholt, Thomas and Kaufeld, Jessica and Menne, Jan and Buxhofer-Ausch, Veronika and Mühlfeld, Anja and Seelow, Evelyn and Schreiber, Adrian and Todorova, Polina and Cukoski, Sadrija and Jabs, Wolfram J and Özcan, Fedai and Gäckler, Anja and Schönfelder, Kristina and Seibert, Felix S and Westhoff, Timm and Schwenger, Vedat and Eichenauer, Dennis A and Völker, Linus A and Brinkkoetter, Paul T},
  title = {Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange},
  journal = {Blood},
  year = {2024},
  volume = {144},
  number = {14},
  pages = {1486--1495},
  doi = {10.1182/blood.2023023780}
}
Kostenlos starten →